PCN Insights, News, Videos, and More

Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”

A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020. 

Contrary to researchers’ expectations, memory loss and accelerated cognitive decline in older adults with major depression are not caused by greater amyloid beta accumulation in the brain, a study suggests.

Children with attention-deficit/hyperactivity disorder (ADHD) who are African American appear to have key genetic differences from those who are Caucasian, according to a study published in Scientific Reports.

The University of California, Berkeley announced that it has opened a center for psychedelic science and public education on its campus. The UC Berkeley Center for the Science of Psychedelics, which was developed with $1.25 million in seed...